Novavax also announced (but did not publish) encouraging results of their Phase III Clinical Trial. Their press release (not published data) said that their clinical trial met the primary endpoints for safety and effectiveness. They said that upcoming results will show that their vaccine candidate was 89% effective in the Phase III clinical trial conducted in the UK.
“With today’s results from our UK Phase 3 and South Africa Phase 2b clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2 and 3 trials involving over 20,000 participants.”
“In addition, our PREVENT-19 US and Mexico clinical trial has randomized over 16,000 participants toward our enrollment goal of 30,000. NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants,” (from Stanley Erck, President and CEO of Novavax.
No word on when the trial data will be published nor when they will ask the FDA for emergency use authorization. This is also an important vaccine as it too has simple storage and handling requirements and is perfect for doctor’s offices, pharmacies, mobile clinics and community health centers.
